Ongoing, recruitingTherapeutic exploratory (Phase II)Interventional

Molecular imaging exploration of ocular angiogenic activity and evaluation of its value in therapeutic follow-up of AMD patients

This research is looking into a new type of body scan to better understand a common eye condition called Age-related Macular Degeneration (AMD). We're using a special scan that can show 'activity' in the eye, which might be linked to the disease getting worse. The study aims to see if this scan can help doctors track the condition and understand if treatments are effective. Participants will have this scan at the start and then again a few months later. We will compare the scan results to their vision and how thick their retina is, to see if the scan gives useful information to improve future care for people with AMD.

At a glance

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Centre Hospitalier Regional De Marseille

Enrolment target

Start

17 Oct 2024

Age-related macular degeneration

What is this study about?

This study is about Age-related Macular Degeneration (AMD), a common eye condition that can affect your central vision. Doctors are always looking for better ways to understand how the disease works and whether treatments are helping.

In this study, we're using a special type of scan, a bit like other body scans you might be familiar with, to look at 'activity' in the eye. This activity is related to tiny blood vessels forming, which can be a problem in AMD. We want to see if this scan can show us what's happening inside the eye and if it can help doctors figure out if a treatment is working well or if more treatment is needed. It’s hoped this could lead to more personalised and effective care for people with AMD.

The main goal is to compare what the scan shows at the beginning of the study with what it shows after a few months. We'll also be checking how these scan results relate to other measures of eye health, such as how clear your vision is and the thickness of the back of your eye. This will help us understand if this new scanning method provides valuable information for doctors treating AMD patients in the future.

Key takeaways

Researchers are exploring a new scanning method for Age-related Macular Degeneration (AMD).
The scan aims to measure 'activity' in the eye related to the disease.
The study hopes to see if this scan can help track AMD and assess treatment effectiveness.
Participants will have two scans and eye checks over a four-month period.
This research could lead to improved understanding and treatment follow-up for AMD.

Who may be eligible?

To take part in this study, you need to be an adult, 18 years old or older. There is no upper age limit, and the study is open to both men and women.

Specific details about your AMD condition, other health issues you might have, or medications you are taking will also be important. The study team will review all of these points to make sure the study is right and safe for you.

It's very important to discuss any health conditions you have with the study team to determine if you can safely participate.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you 18 years old or older?
Have you been diagnosed with Age-related Macular Degeneration (AMD)?
Are you able to attend clinic appointments for scans and eye tests?
Are you comfortable with receiving a small, safe injection for the scan?

Answer every question to see your result.

What does participation involve?

If you decide to take part, you would receive a special, safe dose of a substance called 68Ga-RGD before undergoing a scan. This substance helps highlight the 'activity' in your eye that we want to measure. You would have this scan twice: once at the beginning of the study, and then again four months later. During these visits, your vision will also be checked using standard eye charts, and the doctors will measure the thickness of the back of your eye with another type of scan. The total duration of your active involvement in the study would be about four months.

Potential risks and benefits

Participating in research can offer potential benefits, such as gaining a better understanding of your condition and contributing to medical knowledge that could help others in the future. However, there are potential risks, including side effects from the special substance used for the scan, though these are generally mild. You might also find the study visits time-consuming. You are free to withdraw from the study at any time, for any reason, without it affecting your medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
France

Common questions

What is AMD?

AMD stands for Age-related Macular Degeneration, an eye condition that can affect your central vision, making it harder to see details.

What is this 'special scan'?

It's a type of scan that uses a small amount of a safe substance to highlight specific 'activity' in your eye linked to AMD, helping doctors see how the disease is affecting you.

Will this study cure my AMD?

This study is not a treatment itself; it's about finding better ways to understand and track AMD to improve future treatments for patients.

How many times will I visit the clinic?

You will have two main visits for scans and eye checks: one at the start of the study and another about four months later.

What is 68Ga-RGD?

It's a special substance given before the scan to make certain parts of your eye more visible, helping researchers measure the disease 'activity'.